Repligen (NASDAQ:RGEN) Price Target Raised to $180.00

Repligen (NASDAQ:RGEN) had its price target increased by Canaccord Genuity Group from $145.00 to $180.00 in a report published on Monday, Marketbeat reports. Canaccord Genuity Group currently has a hold rating on the biotechnology company’s stock.

Several other brokerages also recently weighed in on RGEN. Zacks Research downgraded Repligen from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 28th. Weiss Ratings raised Repligen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Wells Fargo & Company increased their price target on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Citigroup raised Repligen to a “buy” rating in a report on Tuesday, July 7th. Finally, JPMorgan Chase & Co. raised their price target on Repligen from $165.00 to $175.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $175.71.

Repligen Stock Performance

RGEN opened at $180.01 on Monday. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. The business’s 50 day moving average is $176.69 and its 200-day moving average is $147.03. The stock has a market cap of $10.16 billion, a PE ratio of 90.80, a price-to-earnings-growth ratio of 3.26 and a beta of 1.08. Repligen has a twelve month low of $100.99 and a twelve month high of $198.87.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The business had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same period in the prior year, the company posted $0.26 EPS. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts predict that Repligen will post 2.06 earnings per share for the current year.

Institutional Trading of Repligen

Several institutional investors have recently modified their holdings of the company. ABS Investment Management LLC bought a new position in Repligen during the second quarter valued at about $191,016,000. CoreCap Advisors LLC raised its position in Repligen by 1,275.0% in the third quarter. CoreCap Advisors LLC now owns 275 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 255 shares in the last quarter. Farther Finance Advisors LLC raised its position in Repligen by 35.5% in the third quarter. Farther Finance Advisors LLC now owns 374 shares of the biotechnology company’s stock worth $72,000 after acquiring an additional 98 shares in the last quarter. Northwestern Mutual Wealth Management Co. acquired a new stake in Repligen in the 2nd quarter valued at about $52,000. Finally, Trust Co. of Vermont acquired a new stake in Repligen in the 2nd quarter valued at about $71,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.